

REMARKS

Reconsideration of the rejections set forth in the Office action mailed October 16, 2006, 2006 is respectfully requested. Claims 34-44 are currently pending. Claims 1-33 have been cancelled. Claim 44 is added with this amendment.

I. Amendments

Independent claim 34 has been amended to specify that the pharmaceutical composition is “suitable for pharmaceutical use in a mammal”, per the definition of “pharmaceutical composition” in the specification at page 12, line 29.

New claim 44 stipulates that the pharmaceutical composition “consists of” a pharmaceutically acceptable carrier and a polynucleotide as recited in independent claim 34; that is, the composition comprises these components and no additional components.

No new matter is added by any of the amendments.

II. Allowable Subject Matter

Claims 38 and 39 were found allowable.

Claims 42 and 43 were objected to as being dependent on a rejected base claim (34), but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Applicants submit that amended claim 34 should be found allowable for the reasons given below.

III. Rejections under 35 U.S.C. §102(b)

Claims 34-36, 40 and 41 were rejected under 35 U.S.C. §102(b) as being unpatentable over Villeponteau *et al.*, U.S. Patent No. 5,776,679.

A. The Claims

Independent claim 34 is directed to a pharmaceutical composition, suitable for pharmaceutical use in a mammal, comprising, in a pharmaceutically acceptable carrier, a polynucleotide comprising a sequence of at least 7 nucleotides that specifically hybridizes to a first nucleotide sequence within an accessible region of the RNA component of a human telomerase (hTR), wherein the accessible region is selected from the group consisting of

nucleotides 137-196, nucleotides 290-319, and nucleotides 350-380 of hTR (SEQ ID NO: 16). The polynucleotide does not hybridize to a nucleotide sequence within a template region of the hTR. The polynucleotide is effective to inhibit the synthesis of telomeric DNA by telomerase.

Dependent claims 35 and 36 further define the length of the sequence specifically hybridizing to the target RNA. Claims 40 and 41, also dependent on claim 34, recite particular regions of SEQ ID NO: 16 to which a sequence of at least 7 nucleotides of the recited polynucleotide specifically hybridizes.

Dependent claim 44 recites a pharmaceutical composition “consisting of” a pharmaceutically acceptable carrier and a polynucleotide as recited in independent claim 34. As stated in the specification (sentence bridging pages 12-13), a pharmaceutically acceptable carrier “refers to any of the standard pharmaceutical carriers, buffers, and excipients...”.

B. The Cited Art

The Office Action points to a PCR reaction mixture described in Villeponteau *et al.* The PCR reaction employs two primers, one of which has the sequence 5'-GTT TGC TCT AGA ATG AAC GGT GGA AG-3'. This sequence is contained within nucleotides 137 – 196 of hTR.

The PCR reaction mixture is described as follows (column 32, line 61 to column 33, line 44; reactive ingredients highlighted):

For a 20 µl PCR reaction with radioactively labeled nucleotides, 1 µl of the **cDNA** prepared in accordance with the procedure of Example 5 was mixed with **20 pmol of primer 1, 20 pmol of primer 2**, 2.5 µl of 2.5 mM **dNTP [= 6.25 nmol]**, 5 µCi of **α-³²P-dATP**, 2 units of **Taq polymerase** (Boehringer-Mannheim), 0.2 µg of **T4 gene 32 protein** (Boehringer-Mannheim), 2 µl of 10x buffer (500 mM KCl, 100 mM Tris-HCl-pH 8.3, and 20 mM MgCl₂), and water to a total volume of 20 µl. One drop of mineral oil was then added to the tube.

Applicants note that 20 pmol of primer would be equivalent to about 0.16 µg, for a polynucleotide having a MW of about 8000 (approx. MW of the cited PCR primer). The amount

of dNTP used in the reaction (6.25 nmol) is equivalent to about 3.1 µg (using an average MW of about 500 per dNTP).

The Examiner maintains that this PCR reaction mixture is a “pharmaceutical composition” as defined in applicants’ specification, containing a “pharmacologically effective amount of an active agent” (i.e. one of the two primers) and a “pharmaceutically acceptable carrier” (i.e. the KCl/Tris/MgCl₂ buffer).

The applicants submit that this PCR reaction mixture, containing reactive components such as nucleotides (dNTP and radioactively labeled dATP), Taq polymerase, and T4 gene 32 protein (a DNA binding protein), some in much greater amounts than the PCR primer, would not be “suitable for pharmaceutical use in a mammal”, a condition which is part of the definition of “pharmaceutical composition” in the specification and which has been added to the language of independent claim 34. (Nor would it be expected that the primer in this reaction mixture would be “pharmacologically effective” in the presence of cDNA to which it is designed to hybridize.)

Dependent claim 44 recites a pharmaceutical composition “consisting of” a pharmaceutically acceptable carrier and a polynucleotide as recited in independent claim 34. As stated in the specification (sentence bridging pages 12-13), a pharmaceutically acceptable carrier “refers to any of the standard pharmaceutical carriers, buffers, and excipients...”. This claim language would clearly preclude components such as dNTPs and Taq polymerase, which would not fall into the category of “standard pharmaceutical carriers, buffers, and excipients”.

Because the prior art references does not teach a composition having all the features of the claimed composition, it does not anticipate the subject matter of the claims. The applicants therefore request that the rejection under 35 U.S.C. §102(b) be withdrawn.

IV. Rejections under 35 U.S.C. §103(a)

Claims 34-37, 40 and 41 were rejected under 35 U.S.C. §103(a) as being unpatentable over Villeponteau *et al.*, U.S. Patent No. 5,776,679, over Skerra, *Nucleic Acids Research* 20:3551-4 (1992), both cited in the previous action. This rejection is respectfully traversed for the following reasons.

A. The Claims

Independent claim 34 and dependent claims 35, 36, 40 and 41 are described above. Claim

37 further limits claim 34 by reciting that the polynucleotide contains a nucleotide analog or a non-naturally occurring nucleotide linkage.

B. The Cited Art

Villeponteau et al. discloses a PCR reaction mixture containing a PCR primer having the sequence 5'-GTT TGC TCT AGA ATG AAC GGT GGA AG-3', which is contained within the accessible region 137 – 196 as defined in the claims. The PCR reaction mixture also contains cDNA to be amplified, nucleotides, an additional primer, Taq polymerase, and T4 gene 32 protein.

As discussed above, such a reaction mixture would not be “suitable for pharmaceutical used in a mammal”, as recited in independent claim 34.

The Examiner also cited the disclosure of Skerra as allegedly providing motivation to modify the above-noted primer sequence of Villeponteau *et al.* with a nucleotide analog or a non-naturally occurring nucleotide linkage (as recited in dependent claim 37). Skerra teaches that modification of a primer with a phosphorothioate linkage improves amplification reactions using DNA polymerases with proofreading ability.

However, this disclosure would not be pertinent to PCR reactions using *Taq* polymerase, which lacks proof-reading activity. (See, for example, Tindall *et al.*, *Biochemistry* **27**(16):6008-13, Aug 9 1988, “Fidelity of DNA synthesis by the *Thermus aquaticus* DNA polymerase”, which states that “the purified polymerase lacks detectable exonucleolytic proofreading activity” (abstract; copy enclosed). A later reference, Bi *et al.*, *Nucleic Acids Research* **26**(12):3073-75 (1998), reiterates that Taq polymerase, the “thermostable DNA polymerase most widely used for PCR”, “lacks proof-reading activity” (second paragraph; copy of article enclosed)).

In view of this, the skilled person would have no reason to modify the primer(s) used in the PCR reaction mixture described in Villeponteau *et al.* along the lines described in Skerra *et al.* The sole purpose of such modification was to prevent degradation of the primers by the 3' to 5' exonuclease (proofreading) activity of the polymerases discussed in Skerra. Such degradation would not be a concern in the cited composition of Villeponteau *et al.*, since Taq polymerase does not have this activity.

Moreover, even if the primer sequence were so modified, the PCR reaction mixture would still not constitute a composition "suitable for pharmaceutical use in a mammal", for the reasons described above.

The remaining claims in this section are all dependent on claim 34 and thus should also be found patentable over these prior art disclosures.

In view of the foregoing, the applicant respectfully requests the Examiner to withdraw the rejections under 35 U.S.C. §103(a).

V. Conclusion

In view of the foregoing, the applicant submits that the claims now pending are now in condition for allowance. A Notice of Allowance is, therefore, respectfully requested.

If in the opinion of the Examiner a telephone consultation would expedite the allowance of the present application, the Examiner is encouraged to call the undersigned at (503) 727-2116.

Date: 2-16-2007


Correspondence Address:

PAYOR NUMBER 22918

Phone (503) 727-2116

Fax (650) 838-4350

Respectfully submitted,



LeeAnn Gorthey

Registration No. 37,337



A service of the National Library of Medicine
and the National Institutes of Health

My NCBI
[Sign In] [Register]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search for

Limits Preview/Index History Clipboard Details

Display Show Sort by Send to

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy
E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: Biochemistry. 1988 Aug 9;27(16):6008-13.

Link

Fidelity of DNA synthesis by the *Thermus aquaticus* DNA polymerase.

Tindall KR, Kunkel TA.

Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709.

We have determined the fidelity of in vitro DNA synthesis catalyzed at high temperature by the DNA polymerase from the thermophilic bacterium *Thermus aquaticus*. Using a DNA substrate that contains a 3'-OH terminal mismatch, we demonstrate that the purified polymerase lacks detectable exonucleolytic proofreading activity. The fidelity of the Taq polymerase was measured by two assays which score errors produced during in vitro DNA synthesis of the lacZ alpha complementation gene in M13mp2 DNA. In both assays, the Taq polymerase produces single-base substitution errors at a rate of 1 for each 9000 nucleotides polymerized. Frameshift errors are also produced, at a frequency of 1/41,000. These results are discussed in relation to the effects of high temperature on fidelity and the use of the Taq DNA polymerase as a reagent for the in vitro amplification of DNA by the polymerase chain reaction.

PMID: 2847780 [PubMed - indexed for MEDLINE]

Display Show Sort by Send to

Related Links

High fidelity DNA synthesis by the *Thermus aquaticus* DNA polymerase. *Nucleic Acids Res.* 1990]

Fidelity of DNA synthesis by the *Thermococcus litoralis* DNA polymerase--an extremely heat stable enzyme with proofreading activity. *Nucleic Acids Res.* 1991]

Exonucleolytic proofreading enhances the fidelity of DNA synthesis by chick embryo DNA polymerase beta. *Science*. 1988]

Accuracy of replication in the polymerase chain reaction. Comparison between *Thermotoga maritima* DNA polymerase and *Thermus aquaticus* DNA polymerase. *Proc Natl Acad Sci USA*. 1998]

Characterization of the 5' to 3' exonuclease associated with *Thermus aquaticus* DNA polymerase. *Nucleic Acids Res.* 1990]

See all Related Articles...

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Feb 7 2007 15:04:00

Detection of known mutation by proof-reading PCR

Wanli Bi and Peter J. Stambrook*

Department of Cell Biology, Neurobiology and Anatomy, University of Cincinnati, College of Medicine, PO Box 670521, Cincinnati, OH 45267-0521, USA

Received February 12, 1998; Revised and Accepted May 4, 1998

ABSTRACT

Proof-reading PCR (PR-PCR) is designed to detect known mutations within genomic DNA. It differs from standard PCR approaches in that one of the two primers has its 3' end aligned with a putative mutation site, and has its 3'-OH replaced by a blocking group. Distinguishing a mutant gene from wild-type depends upon preferential removal of the blocked 3' terminal nucleotide by the polymerase proof-reading activity when it is mismatched with the template. Preferential removal of the blocked nucleotide allows subsequent extension and selective amplification, and provides the basis for distinguishing mutant from normal genes. This method has been used here to detect a transition mutation within the *P53* gene of HaCaT cells with verification by direct sequencing of the selectively amplified DNA.

An ever increasing number of genes that cause inherited and acquired diseases continue to be cloned. Many of these diseases are a consequence of defined mutations where rapid detection for DNA-based diagnosis is becoming increasingly important for monitoring disease, for better defining informed therapeutic options, for counseling and for establishing prevention strategies. Several approaches including restriction enzyme analysis of PCR products (1), allele-specific PCR (AS-PCR) and its derivatives (2,3) and combined chain reaction (CCR) (4) have been developed to detect known mutations in genomic DNA. Here we describe a specialized modification of PCR, proof-reading PCR (PR-PCR), for detecting known mutations.

Fidelity of DNA replication *in vivo* is achieved, in part, by the proof-reading activity of the DNA polymerase. When an errant nucleotide is incorporated and forms a mismatch with the template, it is removed by a 3' to 5' exonuclease proof-reading activity associated with the polymerase. Some thermostable DNA polymerases have proof-reading activity, a characteristic desirable for accurate DNA amplification and for PCR amplification of long DNA sequences (5,6). The thermostable DNA polymerase most widely used for PCR is Taq polymerase, which lacks proof-reading activity.

Efficient proof-reading by the thermostable DNA polymerase is an essential element for PR-PCR (Fig. 1). After denaturation of the target, the two primers are annealed with target sequences. One of the two primers used for amplification is designed to have

its 3' terminal nucleotide aligned with the putative mutation site; however, the terminal 3'-OH group, which is required for the formation of the next phosphodiester bond, is replaced by a blocking group that prevents oligonucleotide extension unless it is removed. If the blocked nucleotide is mispaired, it will be removed by the proof-reading activity, permitting primer extension and subsequent target DNA amplification. In contrast, if the 3' terminal nucleotide is faithfully paired with the template DNA, the blocked nucleotide will be removed inefficiently, if at all, and target DNA amplification will be minimal. Thus, differential amplification is achieved as a consequence of the varying efficiencies of removing the blocked nucleotide. A small difference in amplification efficiency during a single cycle is greatly magnified over 35 cycles, such that the overall difference in amplification can be visualized by ethidium bromide staining after agarose gel electrophoresis.

A known mutation in *P53* of HaCaT cells was targeted for detection by PR-PCR. The HaCaT cell line was established from a human squamous carcinoma (7) and is a compound heterozygote with two different mutant *P53* alleles (8). The mutation targeted for detection was a dinucleotide substitution CC to TT at codon 281-282 in exon 8. There are no mutations in exon 5 through 9 of *P53* of human fibrosarcoma HT1080 cells (9). Since PR-PCR selectively amplifies alleles with a mismatch at the 3' blocked nucleotide, the targeted mutant allele in HaCaT cells should be amplified with the reverse primer 'W' that hybridizes perfectly with the wild-type allele but not with the mutant. In contrast, the normal allele should be amplified with reverse primer M that is a perfect match with the mutant but not wild-type allele. Our prediction was that PR-PCR should amplify *P53* of HaCaT cells with either primer W or primer M because each of these primers forms a mismatch with one of the two alleles because of the compound heterozygosity at this locus. However, *P53* in genomic DNA of HT1080 cells should be amplified only with primer M because the blocked 3' end of this primer forms a mismatch with the template.

Since Taq DNA polymerase does not have the required proof-reading activity for PR-PCR, it cannot excise the 3' blocking group, thereby preventing amplification. As shown in Figure 2a, Taq DNA polymerase can only amplify *P53* of HaCaT cells with an unmodified wild-type but not 3' blocked primer, indicating the requirement for proof-reading activity for PR-PCR.

PR-PCR was tested for its ability to distinguish the normal *P53* allele from a mutant allele containing a CC to TT transition in one of the HaCaT chromosomes. The HT1080 *P53*, which has two

*To whom correspondence should be addressed. Tel: +1 513 558 5685; Fax: +1 513 558 4454; Email: peter.stambrook@uc.edu




Figure 1. Schematic diagram of PR-PCR. As with standard PCR, two primers are used for amplification; however, with PR-PCR the terminal 3'-OH of one of the primers is replaced with a blocking group (x) which prevents exponential amplification in the absence of removal of the blocked terminal nucleotide. To effect excision of the blocked nucleotide, PR-PCR requires use of a DNA polymerase with proof-reading activity. If the blocked 3' nucleotide forms a mismatch with the template, the blocked nucleotide will be removed by the proof-reading activity allowing primer extension and amplification of the target sequence. If the blocked 3' nucleotide hybridizes faithfully with the template, the blocked nucleotide will be removed inefficiently, impeding exponential amplification.

normal alleles at the site targeted, was used as a control. Three blocking chemistries, -3-NH₂, -C₃-SH and -P_i, were tested for efficacy. Selective amplification was achieved with each of these blocking groups (Fig. 2b).

As predicted, HaCaT *P53* was amplified with either blocked wild-type or blocked mutant primer because *P53* is heterozygous at this site. In contrast, HT1080 *P53* was amplified only with blocked mutant primer because HT1080 cells have two normal alleles at the targeted site (Fig. 2b). Although each of the 3' blocked primers tested gave similar amplification patterns, they did show differences, most significantly in ease of excision by 3'→5' exonuclease activity. Of the three blockers tested, -C₃-SH was the most easily removed, -P_i was the most resistant, and -C₃-NH₂ was intermediate (data not shown). Chemical structure, charge or interaction with template and DNA polymerase may all contribute to these differences.

To establish that PR-PCR can detect single nucleotide mutations, PR-PCR was used to identify the C→T transition at codon 282 (nucleotide 14513) at *P53* of HaCaT cells (Fig. 2c). As expected, *P53* from both HaCaT and HT1080 DNAs was amplified when the blocked mutant primer was complementary to the HaCaT mutant allele. However, only HaCaT *P53* was amplified when the blocked primer was wild-type. Again, HaCaT *P53* amplification with blocked mutant primer was expected since HaCaT *P53* is heterozygous, with one of the alleles having wild-type sequence at the targeted site. To verify selectivity of DNA amplification by PR-PCR, HaCaT genomic DNA was amplified with either wild-type or mutant *P53* primer blocked at its respective 3' end.




Figure 2. Detection of known *P53* mutations by PR-PCR. (a) Inability of Taq DNA polymerase (GIBCO-BRL) to extend a primer with a blocked 3' nucleotide. PCR was carried out with Taq DNA polymerase with HaCaT *P53* as a target sequence. BI and OH designate identical primers that differ only in their -C₃-NH₂ blocked (BI) and normal (OH) 3' ends. All reactions were performed in 50 µl containing 1.25 U Taq enzyme in 20 mM Tris-HCl (pH 8.4), 2.0 mM MgCl₂, 100 µg/ml acetylated BSA, 25 mM KCl and 0.2 mM each of NTP. Denaturation was carried out at 94°C for 30 s and annealing and elongation was performed at 65°C for 1, 2, 4 or 6 min. Forward primer: CGTTCACCGAGGACTGGACC; Reverse primer: AGATTCTCTCTCTGTGCGCCGG. (b) PR-PCR detection of a genomic dinucleotide substitution in *P53* using Pfu polymerase (Stratagene, La Jolla, CA). Three blocking groups, -P_i (Perkin-Elmer), -C₃-NH₂ and -C₃-SH (Glenn Research), were compared for efficacy for detection of a CC→TT mutation in genomic *P53* of HaCaT cells. Template HT and Ha represent pre-amplified DNA containing *P53* from HT1080 and HaCaT cells respectively. External primers p53 P1 and p53 P2 are complementary to nucleotides 14 086–14 106 and 14 696–14 950 in the *P53* gene, respectively. W and M designate the diagnostic primers that match faithfully with wild-type and mutant alleles, respectively. The W primer is the wild-type reverse primer presented in the (a) legend above. The mutant reverse primer, M, is identical but with the 3' GG replaced with AA. The reaction conditions were as above except that Taq polymerase was replaced with 2.0 U Pfu. As predicted, HT1080 *P53* amplification is prevented using wild-type primer blocked with any of the three blocking groups. (c) Identification of a single nucleotide transition (C→T) by PR-PCR. Wild-type (W) or mutant (M) primers blocked with a -C₃-NH₂ 3' blocking group were used to amplify *P53* DNA of HT1080 cells (HT) or HaCaT cells (HA) using Pfu polymerase. The HT1080 *P53* was amplified with blocked mutant primer, but not with blocked wild-type primer, whereas HaCaT *P53* was amplified with both due to heterozygosity at this site. Forward primer: CGTTCACCGAGGACTGGAC; Reverse primer: AGATTCTCTCTGTGCTGCCG.

The PR-PCR products were purified and subjected to automated sequencing. The DNA sequence confirmed that the amplification was selective (Fig. 3). Only the mutant allele was amplified with the 3' blocked wild-type primer, while the wild-type allele was amplified with the 3' blocked mutant primer. Thus, PR-PCR can detect a known mutation in genomic DNA efficiently and with high precision.

The introduction of PCR has made possible the selective amplification and analysis of specific DNA sequences from very small amounts of DNA. An additional challenge has been the ability to selectively amplify a mutant sequence from a mixed population of mutant and wild-type DNAs. One approach that has




Figure 3. Sequence verification of PR-PCR selective amplification. Genomic P53 from HaCaT cells was amplified by PR-PCR. The products were purified by Wizard Magic miniprep kit (Promega) and sequenced using an ABI DNA automated sequencer. (a) Selective amplification of the wild-type allele with mutant primer blocked with $-C_3-NH_2$. (b) Selective amplification of the mutant allele with blocked wild-type primer. The arrows identify the target nucleotides.

shown some success is AS-PCR, which can differentiate some mutant genes from wild-type in mixed populations. However, AS-PCR also has its limitations since four out of the 12 potential 3' mismatched ends cannot be elongated effectively (10), and errant elongation leads to false negative or positive results. AS-PCR may extend mismatched primer and produce artifactual templates. In contrast, PR-PCR is based on a different premise and offers an alternative way for achieving selective amplification. In order to achieve substantial amplification with PR-PCR, the blocked 3' nucleotide must be efficiently excised. The preferential removal of the blocked 3' nucleotide at a mismatched end compared with a matched end occurs during each cycle, so that

the accumulative effect over multiple cycles is very large. An additional difference is that in PR-PCR, the actual primer elongation starts at the potential mutation site instead of the neighboring nucleotide as in AS-PCR. Furthermore, the proof-reading activity of Pfu DNA polymerase makes it less likely for unwanted mutations to be introduced than with Taq or other thermostable polymerases that lack proof-reading activity. Given the increasing demands for DNA diagnostics for research, forensics and the clinical setting, development of reliable DNA testing methods that are accurate, sensitive, rapid, non-toxic and amenable to automation remains a continuing challenge. To this end, the strategy employed by PR-PCR provides a promising approach because amplification can be designed to be highly selective, and because procedures and manipulations are simple.

ACKNOWLEDGEMENTS

This work was supported in part by NIH grants P01 ES05652 and R01 CA65769 to P.J.S. W.B. is a fellow of the Albert J. Ryan Foundation.

REFERENCES

- 1 Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T., Erlich, H.A. and Arnheim, N. (1985) *Science*, **230**, 1350-1354.
- 2 Wu, D.Y., Ugozzoli, L., Pal, B.K. and Wallace, R.B. (1989) *Proc. Natl. Acad. Sci. USA*, **86**, 2757-2760.
- 3 Bottema, C.D.K. and Sommer, S.S. (1993) *Mutat. Res.*, **288**, 93-102.
- 4 Bi, W. and Stambrook, P.J. (1997) *Nucleic Acids Res.*, **25**, 2949-2951.
- 5 Barnes, W.M. (1994) *Proc. Natl. Acad. Sci. USA*, **91**, 2216-2220.
- 6 Cheng, S., Fockler, C. and Higuchi, R. (1994) *Proc. Natl. Acad. Sci. USA*, **91**, 5695-5699.
- 7 Boukamp, P., Petrussevska, R.T., Breitkreutz, D., Hornung, J., Markham, A. and Fusenig, N.E. (1988) *J. Cell Biol.*, **106**, 761-771.
- 8 Lehman, T.A., Modali, R., Boukamp, P., Stanek, J., Bennett, W.P., Welsh, J.A., Metcalf, R.A., Stamper, Fusenig, N., Rogan, E.M. and Harris, C.C. (1993) *Carcinogenesis*, **14**, 833-839.
- 9 Sharma, S., Schwarte-Waldhoff, I., Oberhuber, H. and Schafer, R. (1993) *Cell Growth Differ.*, **4**, 861-869.
- 10 Kwok, S., Kellogg, D.E., McKinney, N., Spasic, D., Goda, L., Levenson, C. and Sninsky, J.J. (1990) *Nucleic Acids Res.*, **18**, 999-1005.